Idorsia announces financial results for the first half 2024 Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 25, 2024 Idorsia Ltd (SIX: IDIA) today announced its...
Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call Idorsia will publish its Half Year 2024 Financial Reporting on Thursday July 25, 2024, at 07:00 CEST...
Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension Idorsia receives approval from the European Commission (EC) for JERAYGO™...
Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds Allschwil, Switzerland – June 28, 2024 Idorsia Ltd...
Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June 25, 2024 Idorsia...
Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category Idorsia’s dual orexin receptor antagonist, a...
Idorsia holds its Annual General Meeting of Shareholders All Board proposals approved by the shareholders Allschwil, Switzerland – June 13, 2024At today’s Annual General Meeting (AGM) of Idorsia...
New data with daridorexant to be presented at SLEEP 2024 Allschwil, Switzerland – June 3, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data with daridorexant, Idorsia’s dual orexin...
Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024 Allschwil, Switzerland – May 31, 2024 Idorsia Ltd (SIX: IDIA) today...
Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders Allschwil, Switzerland – May 23, 2024Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.